Related references
Note: Only part of the references are listed.Conformationally constrained peptides target the allosteric kinase dimer interface and inhibit EGFR activation
Melody D. Fulton et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance
Harun Patel et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Structure-Activity Relationship Study of 2,4-Dianilinopyrimidine Containing Methanesulfonamide (TRE-069) as Potent and Selective Epidermal Growth Factor Receptor T790M/C797S Mutant Inhibitor for Anticancer Treatment
Hyeonjeong Choe et al.
BULLETIN OF THE KOREAN CHEMICAL SOCIETY (2017)
Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy
Yoshihisa Kobayashi et al.
CANCER SCIENCE (2016)
Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer
Haa-Na Song et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Yong Jia et al.
NATURE (2016)
Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
Xiaochun Wang et al.
ONCOTARGETS AND THERAPY (2016)
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
Matthew J. Niederst et al.
CLINICAL CANCER RESEARCH (2015)
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Dalia Ercan et al.
CLINICAL CANCER RESEARCH (2015)
Promiscuous 2-Aminothiazoles (PrATs): A Frequent Hitting Scaffold
Shane M. Devine et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing
Robert Tjin Tham Sjin et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Amino acid derived quinazolines as Rock/PKA inhibitors
Sarwat Chowdhury et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States
Antonia F. Stepan et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2011)
Cytochrome P450-Mediated Epoxidation of 2-Aminothiazole-Based AKT Inhibitors: Identification of Novel GSH Adducts and Reduction of Metabolic Activation through Structural Changes Guided by in Silico and in Vitro Screening
Raju Subramanian et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
William Pao et al.
NATURE REVIEWS CANCER (2010)
Asymmetric cyclopropanation of 2,5-dimethyl-2,4-hexadiene by copper catalysts bearing new bisoxazoline ligand
M Itagaki et al.
JOURNAL OF ORGANIC CHEMISTRY (2005)
Share Paper
